Jeannie Woith Discusses the Benefits of Low-Level Laser Therapy for Oral Mucositis

Article

Jeannie Woith, BSN, RN, LMT, The James Cancer Hospital, The Ohio State University, discusses the benefits of treating oral mucositis with low-level laser therapy.

Jeannie Woith, BSN, RN, LMT, The James Cancer Hospital, The Ohio State University, discusses the benefits of treating oral mucositis with low-level laser therapy.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of Hope Rugo, MD
Image of a woman with blond hair in front of a dark blue background
Photo of a woman smiling in front of a dark blue background
Related Content
Image of a laptop with the words "FDA Food and Drug Adminstration" visible

Oncology Drugs Approved by the FDA in June

Bridget Hoyt
July 2nd 2025
Article

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

Shawna Douglas On How Nurse Navigators Help Ease the Treatment Burden for Patients With Head and Neck Cancer

Lindsay Fischer
September 1st 2023
Podcast

Shawna Douglas, BSN, RN, discusses the role that nurse navigators play in caring for patients with head and neck cancer.

Graphic that resembles a stamp of approval reading "FDA Approved"

FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

Bridget Hoyt
June 12th 2025
Article

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

Anatomical graphic of the head and neck with organs visible

Adding Nivolumab to Chemo/RT Yields Higher DFS in Head/Neck Cancer

Ariana Pelosci
June 1st 2025
Article

NIVOPOSTOP trial data demonstrate a reduction in the risk of recurrence or death with adjuvant nivolumab combined with cisplatin/radiotherapy in LA-SCCHN.

Graphic reading "FDA Approved" resembling a stamp of approval

Belzutifan Granted FDA Approval for Pheochromocytoma or Paraganglioma

Bridget Hoyt
May 14th 2025
Article

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma.

Light blue line illustration of a person's nasal cavity on a dark blue background

Eftilagimod Alfa/Pembrolizumab May Improve OS in HNSCC With CPS < 1

Bridget Hoyt
May 5th 2025
Article

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head and neck squamous cell carcinoma.